Remote Ischaemic Preconditioning in Transplantation (RIPTRANS)

Launched by HELSINKI UNIVERSITY CENTRAL HOSPITAL · Feb 24, 2019

Keywords

ClinConnect Summary

The RIPTRANS trial is studying a method called remote ischemic preconditioning (RIPC) to see if it can help improve kidney transplant outcomes. RIPC involves temporarily reducing blood flow to a part of the body to protect other organs, and researchers want to find out if doing this with organ donors can help kidney transplants work better after surgery. This study focuses on brain-dead donors who are giving at least one kidney and aims to see if RIPC can reduce the chances of delayed graft function, which is when a transplanted kidney takes longer to start working.

To be eligible, donors must be brain-dead and planned to donate at least one kidney. Excluded are donors who are unstable or under 18 years old. For organ recipients, they must be over 18, undergo surgery at Helsinki University Hospital, and agree to participate in the trial. If you or your loved one is considering a kidney transplant, this trial could offer valuable insights into improving transplant success. Participants will be part of a carefully monitored process, and their involvement could contribute to better outcomes for future transplant patients.

Gender

ALL

Eligibility criteria

• Donor Inclusion Criteria:
• • Brain-dead organ donor with a plan of harvesting at least one kidney
• Donor Exclusion Criteria:
• • Haemodynamically unstable donor
• • Age below 18 years
• • Planned organ recipients are recruited to another prospective trial, which prevents participation in this trial.
• • All organ recipients receiving organs (kidney, liver, pancreas-kidney, heart, lungs) from a randomized donor will be recruited providing that the recipient surgery is performed at Helsinki University Hospital, recipient is over 18 years old, and recipient gives written informed consent to participate in the trial.